Andrew Doughan, MD
Cardiovascular Disease · McDonough, GANPI 1386843852
Payments from drug & device makers
Across 200 payments — averaging $36.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$4K
- E.r. Squibb & Sons, L.L.C.$537
- United Therapeutics Corporation$368
- Penumbra, Inc.$299
- Heartflow, Inc.$266
- Novartis$265
- plus $2K from 24 others
What the payments were for
- Consulting fees$2,10029%
- Food & beverage$5,12570%
- Education$1122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 63 | $3,711 |
| E.r. Squibb & Sons, L.L.C. | 42 | $537 |
| United Therapeutics Corporation | 8 | $368 |
| Penumbra, Inc. | 2 | $299 |
| Heartflow, Inc. | 2 | $266 |
| Novartis | 15 | $265 |
| Pfizer | 8 | $259 |
| Abbott | 5 | $214 |
| Bayer | 4 | $171 |
| AstraZeneca | 9 | $159 |
| Siemens Medical Solutions USA, Inc. | 1 | $147 |
| Amgen | 3 | $142 |
| Merck | 4 | $140 |
| Astellas Pharma US Inc | 1 | $100 |
| Alnylam Pharmaceuticals Inc. | 4 | $91 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $72 |
| Boehringer Ingelheim | 4 | $66 |
| Johnson & Johnson | 5 | $60 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Cvrx, Inc. | 1 | $31 |
| Abiomed | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Amarin Pharma, Inc. | 1 | $21 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Boston Scientific | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,338 in reported general payments places this provider in the 75th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 56 | $1,289,566 |
| OpsumitMacitentan | 69 | $877,776 |
| EliquisApixaban | 495 | $581,608 |
| VyndamaxTafamidis | 17 | $447,985 |
| AdempasRiociguat | 22 | $410,616 |
| JardianceEmpagliflozin | 184 | $235,807 |
| Ambrisentan | 19 | $165,404 |
| XareltoRivaroxaban | 143 | $145,199 |
| EntrestoSacubitril/Valsartan | 82 | $99,596 |
| Repatha SureclickEvolocumab | 64 | $64,266 |
| FarxigaDapagliflozin Propanediol | 28 | $28,761 |
| WegovySemaglutide | 19 | $24,898 |
| OzempicSemaglutide | 11 | $21,027 |
| BrilintaTicagrelor | 16 | $10,546 |
| Metoprolol Succinate | 633 | $8,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $3,711 | $2,167,342125 claims |
| PfizerEliquis, Vyndamax | $259 | $1,029,594512 claims |
| BayerAdempas | $171 | $410,61622 claims |
| Boehringer IngelheimJardiance | $66 | $235,807184 claims |
| Johnson & JohnsonXarelto | $60 | $145,199143 claims |
| NovartisEntresto | $265 | $99,59682 claims |
| AstraZenecaFarxiga, Brilinta | $159 | $39,30644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in McDonough
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
- David SuhTucker$1.1M
- Michael MorrisAtlanta$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.